RGD Reference Report - Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition

Authors: Chu, YX  Zheng, A  Xi, MR  Zhang, J 
Citation: Chu YX, etal., Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 Mar;37(2):218-20.
RGD ID: 2301231
Pubmed: (View Article at PubMed) PMID:16608079

OBJECTIVE: To explore the relationship between the reduction of FHIT expression of fragile histidine (FHIT) and the development of vulvar carcinoma. METHODS: The expression of the FHIT product was detected by immunochemistry in the tissue samples of 20 normal vulvas, 22 vulvar intraepithelial neoplasias (VINs), and 60 primary vulvar carcinomas. RESULTS: The expressive rates of FHIT protein in the squamous epithelium of normal vulvas, VIN I - II, VIN II, and noninvasive and invasive vulvar carcinoma were 100% (20/20), 72.7% (8/11), 45.5% (5/11), and 21.7% (13/60) respectively (P<0.05). The expressive rates of FHIT protein in the well differentiated, intermediately differentiated and poorly differentiated invasive vulav carcinoma were 60.0% (9/15), 20.0% (3/15), and 3.3% (1/30) respectively (P<0.05). The expressive rate of the impaired FHIT protein in the invasive vulva carcinoma with lymphnode metastasis (10%) was lower than that without lymphnode metastasis (27.5%). CONCLUSION: Abnormal FHIT expression may play an important role in the progression of vulvar carcinoma. The expression of FHIT may provide important information for the prognosis of vulva carcinoma.

Annotation

Disease Annotations    
Vulvar Neoplasms  (IEP,ISO)

Objects Annotated

Genes (Rattus norvegicus)
Fhit  (fragile histidine triad diadenosine triphosphatase)

Genes (Mus musculus)
Fhit  (fragile histidine triad gene)

Genes (Homo sapiens)
FHIT  (fragile histidine triad diadenosine triphosphatase)


Additional Information